Management Comment "This new assault on cancer will be the result of reviewing the 130 or so tumor types that have been characterized and narrowing that list down to four we will develop and targeting one we’ll take into the clinic this year.[...]  I will say that the target is a cancer with very rapid progression after diagnosis and no good treatment alternatives at this time. INO-5400 product will include our hTERT antigen as one of the antigens, as well as two other top antigens from our extensive screening that we’ve done in the last couple of years."-CEO Joseph Kim